AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Targeted vaccine may help immune system fight cancer.(Brief Article)
2002 JUN 12 - (NewsRx.com & NewsRx.net) -- Completing an important step in the evaluation of a cancer vaccine that has the potential to selectively target a wide range of tumors, researchers at the Ludwig Institute for Cancer Research report that the NY-ESO-1 ISCOM vaccine safely activated a specific immune response in most cancer patients.
The results, presented at the American Society of Clinical Oncology annual meeting in Orlando, Florida, demonstrate for the first time that a NY-ESO-1 full-length protein can stimulate anticancer defenses.
"There are a number of vaccine strategies that might work against cancer, but NY-ESO-1 proteins are particularly exciting because they can possibly help a wide range of patients," said the study's lead author, Dr. Jonathan Cebon, of the Ludwig Institute for Cancer Research, Melbourne Branch. "The vaccine showed a clear cause and effect in eliciting both NY-ESO-1-specific antibody and cellular-mediated responses."
To attack cancer, immune cells must recognize antigens located on the surface of tumors. NY-ESO-1, a cancer/testis (CT) antigen, is one of the most recognizable tumor antigens discovered so far. In a previously published study, almost half of all patients with advanced NY-ESO-1 tumors and evidence of cancer showed natural immunity to the antigen. Because CT antigens are found only in tumors and a few normal cells such as those in the testis, vaccines that stimulate an immune response to CT antigens should have little risk of ...
- Lentiviral vector encoding NY-ESO-1 induces effective CTL response.
- Newspaper article from: Cancer Weekly March 30, 2004 700+ words
...injection of a lentiviral vector encoding NY-ESO-1 induces an effective cytotoxic...vector encoding the melanoma antigen NY-ESO-1 in HLA-A2 transgenic mice. Direct iv injection of NY-ESO-1 lentivirus induced NY-ESO-1...
- NY-ESO-1 protein protects against NY-ESO-1+ tumors.
- Newspaper article from: Obesity, Fitness & Wellness Week June 26, 2004 700+ words
...NewsRx.com & NewsRx.net) -- NY-ESO-1 protein formulated in ISCOMATRIX...mediated immunity and protection against NY-ESO-1+ tumors. According to a study from Australia, "NY-ESO-1 is a 180 amino-acid human tumor...
- NY-ESO-1 shows promise as antigen for breast cancer vaccine development.
- Newspaper article from: Biotech Week May 12, 2004 700+ words
...NewsRx.com & NewsRx.net) -- NY-ESO-1 shows promise as an antigen for...in the journal Cancer Research, "NY-ESO-1 is a cancer/testis antigen expressed...cellular immunity in patients with NY-ESO-1-expressing cancer. "The aim...
- Cytotoxic T cell responses toward NY-ESO-1 protein examined.
- Newspaper article from: Health & Medicine Week December 27, 2004 700+ words
...cytotoxic T cell responses toward the NY-ESO-1 protein by peptide/MHC-specific...European Journal of Immunology. "NY-ESO-1 is a germ-cell antigen aberrantly...cells generated in vaccine trials using NY-ESO-1-derived peptides (157-165...
- NY-ESO-1 is promising target for NSCLC immunotherapy.
- Newspaper article from: Biotech Week June 9, 2004 700+ words
...amp; NewsRx.net) -- The antigen NY-ESO-1 is frequently expressed by non...oncologists in Japan explained. "NY-ESO-1 is one of the most immunogenic...examined "mRNA expression status of NY-ESO-1 in 63 cases of NSCLCs using the...
- NY-ESO-1-related HLA A2-restricted epitopes characterized.
- Newspaper article from: Proteomics Weekly August 2, 2004 700+ words
...functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes...According to a study from Australia, "NY-ESO-1, a commonly expressed tumor antigen...vaccine candidate. Peptides derived from NY-ESO-1 have shown preclinical and clinical...
- Vaccine targets ovarian-cancer cells.(BIOMEDICINE)(NY-ESO-1 protein)(Brief...
- Magazine article from: Science News August 25, 2007 700+ words
...cancer. The protein fragment, called NY-ESO-1, appears on the surface of tumor...women received shots containing the NY-ESO-1 vaccine every 3 weeks for a period...primed to attack anything sporting NY-ESO-1. A few of the patients also developed...
- Therion Biologics and the Ludwig Institute Initiate Clinical Study of Cancer...
- Press release article from: PR Newswire January 2, 2002 700+ words
...vaccine targeting the tumor antigen NY-ESO-1. In this study, the Ludwig Institute...evaluate the potential benefits of NY-ESO-1 immunotherapy in cancer patients...products for the treatment of cancer." NY-ESO-1 Study Design The Phase I dose...
